How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,084 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. DNA-based Dietary Advice for Adults With Depressive Disorders

prior to the study, and b) they continue on these agents throughout the study. Supplement information will be presented at intake, and the cessation of any such supplements will be required for the participant to continue in screening. Women who are pregnant or breast-feeding; women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse (for example, intrauterine device, oral contraceptive, implant, Depo-Provera, or barrier devices

2017 Clinical Trials

162. Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), Essure® permanent birth control, and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Exclusion Criteria: Females who are pregnant, breastfeeding, intending

2017 Clinical Trials

163. Feasibility of Outpatient Closed Loop Control With the Bionic Pancreas in Cystic Fibrosis Related Diabetes

the study. Acceptable contraception methods include: Oral contraceptive pill (OCP) Intrauterine Device (IUD, hormonal or copper) Male condoms Female condoms Diaphragm or cervical cap with spermicide Contraceptive patch (such as OrthoEvra) Contraceptive implant (such as Implanon, Nexplanon) Vaginal ring (such as NuvaRing) Progestin shot (such as Depo-Provera) Male partner with a vasectomy proven to be effective by semen analysis Need to go outside of the designated geographic boundaries during the study

2017 Clinical Trials

164. Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions

months prior to Screening) in combination with a barrier method Oral contraceptives, Depo-Provera, Norplant, Patch or intrauterine progesterone contraceptive for at least 90 days prior to screening in combination with a barrier method. Vasectomized partner (6 months minimum since vasectomy) Complete abstinence from heterosexual intercourse. However, if the subject becomes sexually active, 1 of the above methods must be utilized. If a female of non-childbearing potential - should be surgically sterile

2017 Clinical Trials

165. A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

at Screening and Enrollment Per participant report at Screening, regular menstrual cycles with at least 21 days between menses Note: This criterion is not applicable to participants who report using a progestin-only method of contraception at Screening (e.g., Depo-Provera or levonorgestrel-releasing IUD) nor to participants using continuous combination oral contraceptive pills, as the absence of regular menstrual cycles is an expected, normal consequence in this context. Per participant report at Screening

2017 Clinical Trials

166. Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

instructional guide (e.g., spicy foods, thermally hot foods and drinks, hot environments, prolonged sun exposure, strong winds and alcoholic beverages). Non-nursing, female subjects of child bearing potential, who are using an acceptable form of birth control: total abstinence, oral (birth control pills), intravaginal: (e.g. NuvaRing®), implantable (e.g. Norplant®), injectable (e.g. Depo-Provera®) or transdermal (e.g. Ortho Evra®) contraception; intrauterine device (IUD); double-barrier (diaphragm or condom (...) , Valergen, Depo-Testadiol, Depogen, birth control pills), for less than 2 months prior to the Baseline Visit. (Subjects using estrogens for 2 months or more are not excluded unless the subject expected to change dose, drug, or discontinue estrogen use during the study). Use within 2 month prior to the Baseline Visit of 1) topical retinoids to the face, 2) systemic antibiotics known to have an impact on the severity of facial rosacea (e.g., containing tetracycline and its derivatives, erythromycin

2017 Clinical Trials

167. Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence. Exclusion Criteria: Male subjects. Post-menopausal women. Women who do not suffer from acne. Subjects who are allergic to clindamycin, benzoyl peroxide, lidocaine or any other ingredients listed in the study medication. Subjects with an unstable medical condition

2017 Clinical Trials

168. Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise

include:Oral contraceptive pill (OCP), Intrauterine Device (IUD, hormonal or copper), Male condoms, Female condoms, Diaphragm or cervical cap with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days) or other substance abuse (use within

2017 Clinical Trials

169. 18F-FET PET in Childhood Brain Tumours

IntraUterineDevice (IUD), Mirena IUD, Implants, Depo Provera Injections; Persons who are detained officially or legally to an official institute Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03216148 Contacts Layout table for location contacts Contact: Uwe

2017 Clinical Trials

170. Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

: October 31, 2018 See Sponsor: Johns Hopkins University Collaborator: University of Maryland Information provided by (Responsible Party): Johns Hopkins University Study Details Study Description Go to Brief Summary: The investigators are doing a study on the bacteria that normally live in the vagina and what effect, if any, Depo-Provera has on the bacteria. Women 13-24 years of age, who are HIV negative, being seen in a clinic for birth control or sexually transmitted disease (STD) check-up, or have (...) a child and are planning to receive a Depo-Provera shot for contraception or have declined the use of hormonal contraception may join. Condition or disease Intervention/treatment Microbial Colonization Other: No intervention Detailed Description: The investigators are doing a study on the bacteria that normally live in the vagina and what effect, if any, Depo-Provera has on the bacteria. Women 13-24 years of age, who are HIV negative, being seen in a clinic for birth control or STD check-up, or have

2017 Clinical Trials

171. Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

. Intrauterine Device (IUD) PLUS male condom. Provided coils are copper-banded. Acceptable hormonal methods: Normal and low dose combined oral pills PLUS male condom. Cerazette (desogestrel) PLUS male condom. Cerazette is currently the only highly efficacious progesterone based pill. Hormonal shot or injection (e.g., Depo-Provera) PLUS male condom. Etonogestrel implants (e.g. Implanon or Norplan) PLUS male condom. Norelgestromin/ethinyl estradiol (EE) transdermal system PLUS male condom. Intrauterine system

2017 Clinical Trials

172. Use of a Home-based PDG Urine Test to Confirm Ovulation

information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 42 Years (Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Females aged 18 to 42 years Have had a menstrual cycle length of 25-35 days for the past 3 months Are able to provide informed consent Are willing to complete a trial diary Exclusion Criteria: Have current or recent (in the past 6 months) use of any hormonal contraception (e.g. the Pill, Norplant, Depo (...) Provera injections) Have current or recent (in the past 6 months) breastfeeding Have use of emergency contraception (e.g. the morning after pill or Plan B) in the past two menstrual cycles Cannot medically receive frequent blood tests, for example due to a blood clotting disorder Are pregnant at the time of enrollment to study Plan to donate blood during the study Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2017 Clinical Trials

173. PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

at screening Must be in general good health in the opinion of the investigator Regular menstrual cycles of approximately 21 to 35 days apart with no untreated intermenstrual menstrual bleeding Note: This criterion is not applicable to participants using continuous combination oral contraceptive pills or progestin-only methods (such as Depo-Provera or levonorgestrel-releasing IUD), as the absence of regular menstrual cycles is an expected, normal consequence in this context. Satisfactory cervical Pap result

2017 Clinical Trials

174. Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

<50,000; Blood donation (1 pint of whole blood) within the past 2 months; Active alcohol abuse or substance abuse; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera

2017 Clinical Trials

175. The Effect of Benralizumab on Exercise-induced Bronchoconstriction

; Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device/levonorgestrel Intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™ or Nuvaring™. WOCBP must agree to use effective method of birth control, as defined above, from enrolment

2017 Clinical Trials

176. A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

, e.g., use of oral contraceptives with an additional barrier method (since the study drug may impair the effectiveness of oral contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy, total abstinence, and willing to continue the effective contraception method for 30 days after the last dose of study drug; Ability to understand and provide signed informed consent that fulfills Institutional Review Board's

2017 Clinical Trials

177. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

treatment and for 6 months following the last dose of rucaparib; the following are allowable only: Ongoing use of progesterone-only injectable or implantable contraceptives (eg, Depo Provera, Implanon, Nexplanon) Placement of an intrauterine device or intrauterine system Bilateral tubal occlusion Sterilization, with appropriate post-vasectomy documentation of absence of sperm in ejaculate True, complete (as opposed to periodic) abstinence Exclusion Criteria: Any of the following: Pregnant individuals

2017 Clinical Trials

178. Hybrid Closed Loop Insulin Delivery System in Hypoglycemia

. Oral contraceptives, intra-uterine devices, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment. Use of any investigational agents within 4 weeks of enrollment. Any medical condition that, in the opinion of the PI, will interfere with the safe completion of the study Contacts and Locations Go to Information from

2017 Clinical Trials

179. AMP002 Phase III Contraceptive Study

breastfeeding, she must have demonstrated return to regular cycling and have had at least three consecutive, spontaneous menses post lactation prior to the date of consent. If the subject received prior administration of injectable contraceptives (e.g., depot-medroxyprogesterone acetate [DMPA], Depo Provera), there must be at least 10 months since the last injection and the subject must have had at least two consecutive, spontaneous menses prior to the date of consent. If a contraceptive implant

2017 Clinical Trials

180. Adrenergic System in Islet Transplantation

daily, or an equivalent physiologic dose of hydrocortisone. For female participants of child-bearing potential: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of study participation. Oral contraceptives, intra-uterine devices, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Treatment with any anti-diabetic medication other than (...) contraceptive measures for the duration of study participation. Oral contraceptives, intra-uterine devices, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment. Use of any investigational agents within 4 weeks of enrollment. Any medical condition that, in the opinion of the PI, will interfere with the safe completion of the study

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>